Mostrar el registro sencillo del ítem

dc.rights.licenseopenen_US
dc.contributor.authorDEVILLIER, Philippe
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorMOLIMARD, Mathieu
dc.contributor.authorBERGMANN, Jean-Francois
dc.contributor.authorDELAISI, Bertrand
dc.contributor.authorGOUVERNEUR, Amandine
dc.contributor.authorVADEL, Jade
dc.contributor.authorCOLLIN, Cedric
dc.contributor.authorGIRARD, Laurence
dc.contributor.authorSCURATI, Silvia
dc.contributor.authorDEMOLY, Pascal
dc.date.accessioned2024-05-13T09:01:51Z
dc.date.available2024-05-13T09:01:51Z
dc.date.issued2023-12-19
dc.identifier.issn1744-8409en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/199772
dc.description.abstractEnBACKGROUND: The only causal treatment for allergic rhinitis (AR) is allergen immunotherapy (AIT) including personalized liquid sublingual AIT (SLIT). We present the methodology for establishing the EfficAPSI cohort to further evaluate the real-life effectiveness and use of SLIT liquid. RESEARCH DESIGN AND METHODS: The EfficAPSI cohort was constituted by deterministic linkage of Stallergenes Greer dispensing and nationwide French healthcare insurance system (SNDS) databases. Data from 2006 to 2018 were extracted. All patients who initiated Stallergenes Greer SLIT liquid between 2010 and 2013 were considered as exposed and those dispensed with AR symptomatic treatment only as control. To limit the impact of confounding, the models will be weighted using the inverse probability of treatment weighting (IPTW). RESULTS: A total of 445,574 patients were included; median age was 38 years; 59.1% were female. Exposed patients (n = 112,492) were significantly younger, more frequently males, and less likely to have comorbidities than controls (n = 333,082). After IPTW, patients' characteristics from both groups were similar. CONCLUSIONS: To date, the EfficAPSI cohort has the largest number of person-years of follow-up in the field of AIT. The completeness of the data allows to evaluate SLIT liquid effectiveness with rigorous methodology, leading to important insights on personalized medicine in real-life.
dc.language.isoENen_US
dc.rightsAttribution-NonCommercial-NoDerivs 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/us/*
dc.subject.enAsthma
dc.subject.enPharmacoepidemiology
dc.subject.enPrecision Medicine
dc.subject.enRhinitis
dc.subject.enAllergic
dc.subject.enSublingual Immunotherapy
dc.title.enA successful linkage of a named patient products of sublingual immunotherapy-dispensing registry to French healthcare insurance database (SNDS): methodological constitution of the EfficAPSI cohort
dc.title.alternativeExpert Rev Clin Immunolen_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1080/1744666x.2023.2294040en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed38112340en_US
bordeaux.journalExpert Review of Clinical Immunologyen_US
bordeaux.page405-412en_US
bordeaux.volume20en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.issue4en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.teamAHEAD_BPHen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.popularnonen_US
hal.audienceInternationaleen_US
hal.exportfalse
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Expert%20Review%20of%20Clinical%20Immunology&rft.date=2023-12-19&rft.volume=20&rft.issue=4&rft.spage=405-412&rft.epage=405-412&rft.eissn=1744-8409&rft.issn=1744-8409&rft.au=DEVILLIER,%20Philippe&MOLIMARD,%20Mathieu&BERGMANN,%20Jean-Francois&DELAISI,%20Bertrand&GOUVERNEUR,%20Amandine&rft.genre=article


Archivos en el ítem

Thumbnail
Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem